Market Size of Global Immunomodulators Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.40 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Immunomodulators Market Analysis
The immunomodulators market is expected to register a CAGR of 5.4% over the forecast period 2022-2027.
The coronavirus disease (COVID-19) pandemic has affected the market for immunomodulators adversely. The article 'COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs' published in 2022, by the British Journal of Ophthalmology, explains that immune suppressants have been widely used by doctors to treat chronic inflammatory illnesses, it does come with a few drawbacks, one of which is an increased risk of infection. Additionally, tt is crucial that doctors should properly give instructions to patients while taking medications considering the present COVID-19 outbreak. Hence, the market of immunomodulators has been impacted during the COVID outbreak.
Further, the increasing rate of diseases post covid caused the immunomodulator market to grow at a faster pace. The article 'Immunotherapies and immunomodulatory approaches in clinical trials - a mini review' published in the Human Vaccines & Immunotherapeutics journal in 2021, reveals that due to the respiratory issues developed after covid in many patients despite age group lead to the rise of immunotherapies when there was limited availability of vaccines. Immunotherapies employing convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to boost immunity are valuable alternatives due to the lack of any vaccine or medicines against COVID-19.
Increasing Incidence of Chronic Diseases Such as Asthma, Allergic Conditions, Cancer, and Multiple Sclerosis causes the immunomodulators market to grow, for instance, the research published in American Cancer Society points out that because of population expansion and ageing, it is anticipated that by 2040 there would be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide. Due to the rising frequency of risk factors like smoking, poor food, and physical inactivity in economically developing nations, the burden will likely grow in the future.
Furthermore, market players are engaged in marketing tactics such as mergers and acquisitions, as well as product launches for instance in October 2019, Pandion Therapeutics, Inc. and Astellas Pharma Inc. signed a license and collaboration agreement to collaborate on the discovery, production, and marketing of locally acting immunomodulators for pancreatic autoimmune disorders. For the treatment of autoimmune conditions, the agreement will allow the parties to integrate Pandion's modular biologics and functional immunology knowledge with Astellas' advanced medicines development and worldwide marketing expertise.
The evaluated market is expected to grow throughout the analysis period for the reasons stated. However, unfavorable regulatory policies limit the growth of the immunomodulators industry.
Immunomodulators Industry Segmentation
As per the scope of the report, immunomodulators are the agents that can enable the body fight cancer, infection, or other disorders by stimulating or suppressing the immune system. The immunomodulators market is segmented by Product Type (Immunosuppressants, Immunostimulants, Other Product Types), Application (Oncology, Respiratory, HIV, Other Applications) End Users (Hospitals, Clinics & Other End Users), Geography (North America, Europe, Asia-Pacific, South America, Middle East, and Africa). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Immunosuppressants | |
| Immunostimulants | |
| Other Product Types |
| By Application | |
| Oncology | |
| Respiratory | |
| HIV | |
| Other Applications |
| By End-User | |
| Hospitals | |
| Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Immunomodulators Market Size Summary
The immunomodulators market is poised for growth, driven by the increasing incidence of chronic diseases such as asthma, cancer, and multiple sclerosis, alongside the rising demand for immunotherapies post-COVID-19. The pandemic initially posed challenges to the market, as immunosuppressants were linked to heightened infection risks. However, the subsequent surge in respiratory issues and the limited availability of vaccines accelerated the adoption of immunomodulatory treatments. Market players are actively engaging in strategic collaborations and product launches to enhance their offerings, as seen in partnerships like that between Pandion Therapeutics and Astellas Pharma. Despite these advancements, regulatory challenges continue to pose obstacles to market expansion.
North America leads the immunomodulators market, attributed to the high prevalence of autoimmune diseases and robust clinical trials in the region. The presence of key manufacturers and the introduction of new products, such as Biocon's Tacrolimus capsules, further bolster market growth. The competitive landscape is characterized by a mix of global and regional players, including Pfizer Inc., Astellas Pharma Inc., and Horizon Therapeutics plc. Recent acquisitions, like Merck's purchase of Pandion Therapeutics, highlight the industry's focus on expanding pipelines to address a wide range of autoimmune conditions. As research and development efforts continue, the market is expected to experience sustained growth, driven by innovations in immunomodulatory therapies.
Global Immunomodulators Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Incidence of Chronic Diseases Such as Asthma, Allergic Conditions, Cancer, and Multiple Sclerosis
-
1.2.2 Emergence of Research and Development in the Field of Immunomodulators
-
-
1.3 Market Restraints
-
1.3.1 Adverse Effect of Drugs
-
1.3.2 Unfavourable Regulatory Policies
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product Type
-
2.1.1 Immunosuppressants
-
2.1.2 Immunostimulants
-
2.1.3 Other Product Types
-
-
2.2 By Application
-
2.2.1 Oncology
-
2.2.2 Respiratory
-
2.2.3 HIV
-
2.2.4 Other Applications
-
-
2.3 By End-User
-
2.3.1 Hospitals
-
2.3.2 Clinics
-
2.3.3 Other End Users
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Immunomodulators Market Size FAQs
What is the current Global Immunomodulators Market size?
The Global Immunomodulators Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)
Who are the key players in Global Immunomodulators Market?
Pfizer Inc, Horizon Therapeutics plc., Astellas Pharma Inc., Acrotech Biopharma, LLC and Petrovax are the major companies operating in the Global Immunomodulators Market.
